Rankings
Pricing
Log In
Free Trial
US-listed companies
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc.
XERS
Market cap
$408.85M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2021
Dec 31,
2022
Jun 30,
2023
Net loss
-123
-95
-37
Depreciation and amortization
1
1
1
Amortization of Intangible Assets
1
11
5
Amortization of investments
-0
-0
1
Amortization of debt issuance costs
1
2
1
Amortization of operating right-of-use assets
-
0
0
Deferred income tax benefit
-
-1
-
Stock-based compensation
11
12
5
Loss on extinguishment of debt
-
-1
-
Loss on disposal of property and equipment
-
-0
-
Gain on the remeasurement of lease liabilities
-
1
-
Change in fair value of warrants
-
2
-0
Change in fair value of contingent value rights
-
3
-2
Trade accounts receivable
6
13
-1
Increase (Decrease) in Prepaid Expense
-3
4
-1
Inventory
7
7
11
Accounts payable
6
-4
7
Other accrued liabilities
13
-11
-11
Accrued trade discounts and rebates
4
2
-
Accrued returns reserve
1
7
0
Supply agreement liabilities
-
-5
-7
Operating lease liabilities
-
-1
6
Other
-1
3
1
Net cash used in operating activities
-96
-103
-40
Capital expenditures
-
-1
-2
Payments to Acquire Investments
43
-
44
Sales and maturities of investments
104
35
10
Cash Acquired from Acquisition
38
-
-
Net cash used in investing activities
98
34
-36
Proceeds from equity offerings
27
30
-
Payments of Stock Issuance Costs
0
-
-
Proceeds from issuance of debt
-
146
-
Repayments of Long-term Debt
-
43
-
Payments of debt issuance costs
-
5
-
Payments for loss on extinguishment of debt
-
1
-
Proceeds from Stock Plans
1
1
1
Proceeds from Stock Options Exercised
0
0
0
Repurchase of common stock withheld for taxes
1
0
1
Net cash provided by financing activities
27
127
-0
Increase (decrease) in cash and cash equivalents
-
59
-76
Cash paid for interest
7
11
15
Issuance Of Warrants For Loan Agreement
-
2
-
Initial operating lease right-of-use assets for adoption of ASU 2016-02
-
6
-
Operating Lease Liabilities Incurred During Period
-
14
-
Stock issued in connection with the Acquisition
138
-
-
Noncash Or Part Noncash Acquisition, Equity Assumed
9
-
-
Noncash or Part Noncash Acquisition, Debt Assumed
23
-
-